Pharmaceutical company Upsher-Smith Laboratories LLC revealed on Friday the launch of an exclusive agreement with a pharmaceutical partner to market and distribute a group of six ophthalmic and otic ANDA products, with combined annual sales of more than USD1.6bn (IQVIA, 12 months ending March 2018).
This partnership collaboration is part of its company-wide effort to grow its generics pipeline as well as expand its strategic relationships within the pharmaceutical industry.
The agreement allows Upsher-Smith to register the products with the US Food and Drug Administration (FDA) as well as market and distribute them under its own label in the US upon US FDA approval.
In conjunction, the partner company will develop and manufacture the products exclusively for Upsher-Smith.
Financial terms related to the deal have not been disclosed by the companies.
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval
Newbury Pharmaceuticals gains Finnish approval for generic melatonin
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment